Array BioPharma
Array BioPharma is a clinical stage publicly traded pharmaceutical company (NASDAQ:ARRY)[1] that is in the NASDAQ Biotechnology Index and is worth 600 million dollars.[2]
| Drug Name | Stage in Clinical Trials | Partnership? (Whom) | Indication |
|---|---|---|---|
| Binimetinib | Phase 3 | None | Cancer |
| Encorafenib | Phase 3 | Pierre Fabre | Cancer[3][4] |
| Selumetinib | Phase 3 | AstraZenca | Cancer |
| Filanesib | Phase 2 | No | Multiple Myeloma[5] |
| ARRY-797 | Phase 2 | No | LMNA-related DCM |
| ARRY-502 | Phase 2 | No | Asthma |
| Ipatasertib | Phase 2 | Genetech | Cancer |
| Motolimod | Phase 2 | VentiRX, Celgene | Cancer |
| Varlitinib | Phase 2 | ASLAN | Cancer |
| Danoprevir | Phase 2 | Roche | Hepatitis C |
| LY2606368 | Phase 2 | Eli Lilly | Cancer |
| LOXO-101 | Phase 2 | Loxo Oncology | Cancer |
| ARRY-382 / CSF1R | Phase 1 | No | Cancer |
| ARRY-614 | Phase 1 | No | MDS |
| ONT-380 | Phase 1 | Oncothyreon | Breast Cancer |
| GDC-0575 | Phase 1 | Genetech | Cancer |
| GDC-0994 | Phase 1 | Genetech | Cancer |
References
- ↑ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ↑ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 3 January 2016.
- ↑ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
- ↑ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
- ↑ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.
- ↑ "Product Pipeline".
This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.